Myriad Genetics' Stock Drops on SCOTUS Decision; Analysts Mixed on Implications | GenomeWeb

NEW YORK (GenomeWeb News) – Shares of Myriad Genetics slid as much as 18 percent today following the decision by the US Supreme Court invalidating the company's patents covering the BRCA1 and BRCA2 genes.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: new single-cell RNA sequencing technique to study proliferating cells, and more.

South African researchers uncover bone cancer in an ancient hominin ancestor.

English bulldogs suffer from low genetic diversity and might have to be outbred to improve their health, according to a new study.

Theresa May tries to reassure researchers about the UK's commitment to science, New Scientist reports.